Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this trial is to test the efficacy and safety of crizanlizumab in patients hospitalized with COVID-19.
Description: Level of soluble P-selectin in ng/ml.
Measure: Soluble P-selectin level Time: Day 3 after randomization or day of hospital discharge, whichever is earlierDescription: Level of soluble P-selectin in ng/ml.
Measure: Soluble P-selectin level Time: Day 7 after randomizationDescription: Level of soluble P-selectin in ng/ml.
Measure: Soluble P-selectin level Time: Day 14 after randomizationDescription: Level of D-dimer in mg/L.
Measure: D-dimer level Time: Day 7 after randomizationDescription: Level of D-dimer in mg/L.
Measure: D-dimer level Time: Day 14 after randomizationDescription: Level of VWF antigen (percentage).
Measure: VWF level Time: Day 7 after randomizationDescription: Level of VWF antigen in (percentage).
Measure: VWF level Time: Day 14 after randomizationDescription: Level of C-reactive protein (CRP) in mg/dL.
Measure: CRP level Time: Day 7 after randomizationDescription: Level of C-reactive protein (CRP) in mg/dL.
Measure: CRP level Time: Day 14 after randomizationDescription: Change in the clinical status over 14 days as measured by an ordinal scale that is the first assessment of the clinical status on a given study day. The scale is as follows: 0 = Uninfected; no viral RNA detected = Ambulatory; asymptomatic; viral RNA detected = Ambulatory; symptomatic; independent = Ambulatory; symptomatic; assistance needed = Hospitalized; no oxygen therapy = Hospitalized; oxygen by mask or nasal prongs = Hospitalized; oxygen by non-invasive ventilation (NIV) or high flow = Hospitalized; intubation and mechanical ventilation, partial pressure of oxygen / fraction of inspired oxygen (pO2/FIO2) ≥ 150 or oxygen saturation / FIO2 (SpO2/FIO2) ≥ 200 = Hospitalized; intubation and mechanical ventilation, pO2/FIO2 < 150 or SpO2/FIO2 < 200 or vasopressors = Hospitalized; intubation and mechanical ventilation, pO2/FIO2 < 150 or SpO2/FIO2 < 200 and vasopressors, dialysis, or extracorporeal membrane oxygenation (ECMO) = Dead
Measure: Change in clinical status as assessed by the World Health Organization (WHO) Ordinal Scale for COVID-19 Trials Time: Daily up to day 14 after randomizationDescription: Time (days) to hospital discharge
Measure: Time to hospital discharge Time: Up to 30 days after randomizationDescription: Safety of crizanlizumab will by assessed by adverse events, serious adverse events, and suspected unexpected serious adverse reactions.
Measure: Safety of Crizanlizumab as assessed by adverse events Time: Up to day 14 after randomizationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports